The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis
- 530 Downloads
BACKGROUND: Exogenous melatonin has been increasingly used in the management of sleep disorders.
PURPOSE: To conduct a systematic review of the efficacy and safety of exogenous melatonin in the management of primary sleep disorders.
DATA SOURCES: A number of electronic databases were searched. We reviewed the bibliographies of included studies and relevant reviews and conducted hand-searching.
STUDY SELECTION: Randomized controlled trials (RCTs) were eligible for the efficacy review, and controlled trials were eligible for the safety review.
DATA EXTRACTION: One reviewer extracted data, while the other verified data extracted. The Random Effects Model was used to analyze data.
DATA SYNTHESIS: Melatonin decreased sleep onset latency (weighted mean difference [WMD]: −11.7 minutes; 95% confidence interval [CI]: −18.2, −5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: −38.8 minutes; 95% CI: −50.3, −27.3; n=2) compared with people with insomnia (WMD: −7.2 minutes; 95% CI: −12.0, −2.4; n=12). The former result appears to be clinically important. There was no evidence of adverse effects of melatonin.
CONCLUSIONS: There is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less); however, additional large-scale RCTs are needed before firm conclusions can be drawn. There is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome with short-term use. There is evidence to suggest that melatonin is safe with short-term use (3 months or less).
Key Wordsmelatonin sleep primary review
Unable to display preview. Download preview PDF.
- 1.National Institutes of Health. National Center on Sleep Disorder Research Plan. 2003.Google Scholar
- 2.Roller L. Treating sleep disorders. Aust J Pharm. 2002;83:443–7.Google Scholar
- 3.American Psychiatric Association. American Psychiatric Task Force on DSM-IV, Diagnostic and Statistical Manual of Mental Disorders: DSM IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
- 4.Grustein R. Insomnia diagnosis and management. Aust Fam Phys. 2002;31:995–1000.Google Scholar
- 5.American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Revised. Diagnostic and Coding Manual. Rochester, Minn: American Academy of Sleep Medicine; 2001.Google Scholar
- 8.Reite M, Ruddy J, Nagel K. Evaluation and Management of Sleep Disorders. 3rd ed. Washington, DC: American Psychiatric Publishing Inc; 2002.Google Scholar
- 20.Deeks JJ, Higgins JPT, Altman DG. Cochrane Statistical Methods Group. Analysing and presenting results: Section 8. In: Alderson P, Green S, Higgins JPT, eds. Cochrane Reviewer’s Handbook 4.2.2 [updated March 2004]; The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons Ltd.; 2004.Google Scholar
- 22.Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in context. 3rd ed. London: BMJ Publishing Group; 2001:285–312.Google Scholar
- 31.Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. Child Neurol. 2001;16:86–92.Google Scholar
- 34.Montes LG, Ontiveros Uribe MP, Cortes Sotres J, Heinze Martin G. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatr Neurosci. 2003;28:191–6.Google Scholar
- 35.Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ). 2004;108:1–7.Google Scholar